- Annual report 2007/2008
-
Annual report 2008/2009
- 2008/2009 In brief
- President’s comments
- Hemtex share
- Presentation of operations
- Board of Directors’ report
- Income statements
- Balance sheets
- Changes in consolidated shareholders’ equity
- Changes in Parent Company shareholders’ equity
- Cash-flow statements
-
Notes
- Note 1 - Accounting principles
- Note 2 - Segment reporting
- Note 3 - Other operating income
- Note 4 - Employees and personnel costs
- Note 5 - Fees to auditors
- Note 6 - Depreciation/amortization of tangible and intangible fixed assets
- Note 7 - Exchange-rate differences that affected profits
- Note 8 - Net financial items
- Note 9 - Appropriations
- Note 10 - Taxes
- Note 11 - Earnings per share
- Note 12 - Intangible fixed assets
- Note 13 - Tangible fixed assets
- Note 14 - Financial fixed assets
- Note 15 - Deferred tax assets/deferred tax liabilities
- Note 16 - Prepaid expenses and accrued income
- Note 17 - Shareholders’ equity
- Note 18 - Untaxed reserves
- Note 19 - Liabilities to credit institutions
- Note 20 - Overdraft facilities
- Note 21 - Derivative held for hedging
- Note 22 - Accrued expenses and deferred income
- Note 23 - Pledged assets
- Note 24 - Contingent liabilities
- Note 25 - Leasing fees relating to operational leasing
- Note 26 - Adjustments for non-cash flow items
- Note 27 - Transactions not entailing payment
- Note 28 - Paid interest
- Note 29 - Acquisition of subsidiaries/operations
- Note 30 - Financial risks and risk policies
- Note 31 - Transactions with related parties
- Note 32 - Events after the closing date
- Note 33 - Important estimates and assessments
- Note 34 - Proposed dividend to shareholders
- Note 35 - Information about the Parent Company
- Note 36 - Definitions of key data
- Nine-year summary
- Proposed distribution of earnings
- Audit report
- Board of Directors
- Corporate Governance
- Management
- Hemtex stores
- Information about the AGM
- Annual reports archive
- Annual report 2009
- Annual Report 2010
- Annual Reports archive
Note 11 - Earnings per share
| Group | |||
| 2006/07 | 2007/08 | 2008/09 | |
| Profit/loss for the year | 159,527 | 96,468 | – 42,940 |
| Base for calculation of earnings per share before dilution | 159,527 | 96,468 | – 42,940 |
| Average number of shares before dilution | 28,017,400 | 29,153,466 | 29,337,400 |
| Earnings per share before dilution | 5.69 | 3.31 | – 1.46 |
| Base for calculation of profit per share after dilution | 159,527 | 96,468 | – 42,940 |
| Average number of shares after dilution | 29,138,829 | 29,153,466 | 29,337,400 |
| Earnings per share after dilution | 5.47 | 3.31 | – 1.46 |
| Calculation of average number of shares | Group | ||
| 2006/07 | 2007/08 | 2008/09 | |
| Opening number of shares on May 1 | 28,017,400 | 28,017,400 | 29,337,400 |
| New share issue, June 2007 | — | 1,320,000 | — |
| Closing number of shares on April 30 | 28,017,400 | 29,337,400 | 29,337,400 |
| Average number of shares for the period | 28,017,400 | 29,153,466 | 29,337,400 |
| Additional shares due to dilution effect | 1,121,429 | — | — |
| Average number of shares for the period after dilution | 29,138,829 | 29,153,466 | 29,337,400 |
No own shares were acquired or transferred during the year. As of April 30, 2009, neither Hemtex AB nor any company in the Group held shares in Hemtex AB. Hemtex AB has only one class of shares in which all shares have the same number of votes per share.
In addition to the number of shares at the end of the period, a number of potential shares are outstanding, attributable to the warrants described in Note 4. A dilution effect arises if the present value of the subscription price is lower than the fair value of the common shares. The dilution effect appears as the difference between the number of shares that holders of warrants have a right to subscribe for and the number of shares valued at fair value, to which the subscription settlement corresponds. The difference is treated as share issues for which the company does not receive any payment.